Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $19.78 Analyst target: $71.00 Upside: 258.95%
Tectonic Therapeutic, Inc. engages in the discovery of antibodies and other biologic drugs targeting G-protein-coupled receptors (GPCRs) to develop novel therapies for patients inadequately served by current treatments. The company is headquartered in Watertown, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.